Effectiveness of evocalcet for hypercalcemia in patients with primary hyperparathyroidism
Endocrine Journal · 2025
DOI: 10.1507/endocrj.ej25-0159 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine Journal, 2025. Verfasst von Kenichi Tanaka und 6 weiteren Autor:innen. Beteiligte Einrichtung: First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan. Hauptthemen laut MEDLINE: Hyperparathyroidism, Primary, Hypercalcemia, Naphthalenes, Calcimimetic Agents. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
- Department of Rheumatology and Diabetes, Wakamatsu Hospital of the University of Occupational and Environmental Health, Kitakyushu, Japan.
- Clinical Research Center, Hospital of the University of Occupational and Environmental Health, Kitakyushu, Japan.
Zitieren
APA
Tanaka, K., Okada, Y., Koikawa, K., Uemura, F., Sumikawa, M., Torimoto, K., & Tanaka, Y. (2025). Effectiveness of evocalcet for hypercalcemia in patients with primary hyperparathyroidism. Endocrine Journal. https://doi.org/10.1507/endocrj.ej25-0159
Vancouver
Tanaka K, Okada Y, Koikawa K, Uemura F, Sumikawa M, Torimoto K, et al. Effectiveness of evocalcet for hypercalcemia in patients with primary hyperparathyroidism. Endocrine Journal. 2025. doi:10.1507/endocrj.ej25-0159
BibTeX
@article{Tanaka2025,
author = {Tanaka, Kenichi and Okada, Yosuke and Koikawa, Kenji and Uemura, Fumi and Sumikawa, Maiko and Torimoto, Keiichi and Tanaka, Yoshiya},
title = {Effectiveness of evocalcet for hypercalcemia in patients with primary hyperparathyroidism},
journal = {Endocrine Journal},
year = {2025},
doi = {10.1507/endocrj.ej25-0159}
}
EUVIMED